CareStart Rapid Antigen Test

CareStart Rapid Antigen Test, Access Bio
https://www.peachmedicalsourcing.com/carestart
FDA Status: EUA Authorized: October 8, 2020
Test Type: Rapid Antigen; Nucleocapsid20 ASSAY BUFFER

Fast, accurate, point-of-care results.
CareStart rapid antigen test is CLIA Waiver and point-of-care authorized. With results in 10 minutes and a visual readout with no analyzer required, CareStartTM is the fastest way to diagnosis COVID-19. More details, pricing, and availability soon.

Manufacturer Background
CareStart was established in 2002 and is headquartered in Somerset, New Jersey, United States. The company specializes in point-of-care IVD tests and is a recognized world leader in providing affordable, accurate testing products. Access Bio has partnered with WHO, UNICEF, Global Fund, MSF, Doctors Without Borders, and the Bill & Melinda Gates Foundation to provide its products to underserved populations.

CareStart Rapid Antigen Test: Access Bio

This is a point-of-care authorized test. CLIA-certified laboratories with Waiver, Moderate, or High Complexity certification may perform the test at point-of-care or in a laboratory setting.

Time to Result: 10-15 minutes

Sample Types:

• Nasopharyngeal swab
• Controls
• Internal control line appears when test is ready
  to be read.